Pain of endometriosis: effects of nafarelin and danazol therapy

What Was Tested

The paper reports a study of Nafarelin in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are teenagers, adults and middle-aged adults, women only.

PATIENTS, SETTING, TREATMENTS: Two hundred thirteen patients aged 18 to 48 with laparoscopically confirmed pelvic endometriosis and dysmenorrhea, dyspareunia or pelvic pain were randomly assigned to 6 months of treatment with either nafarelin acetate 800 micrograms per day or 400 micrograms per day, or danazol 800 micrograms per day.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Nafarelin group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Nafarelin, so expectations could not easily colour the readings.

Prospective, randomized double-blind controlled study.

What Was Measured

PubMed files the paper under topics including Danazol, Dysmenorrhea, Dyspareunia, Endometriosis, Nafarelin, Pain Measurement and Pelvic Pain.

What This Means in Plain Language

The paper is a randomized and double-blind study of Nafarelin in people with endometriosis.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (International journal of fertility and menopausal studies), a journal based in United States.

More context: the Nafarelin compound page, Endometriosis research.